Stay updated on Avapritinib vs Placebo in Indolent Systemic Mastocytosis Clinical Trial
Sign up to get notified when there's something new on the Avapritinib vs Placebo in Indolent Systemic Mastocytosis Clinical Trial page.

Latest updates to the Avapritinib vs Placebo in Indolent Systemic Mastocytosis Clinical Trial page
- Check6 days agoChange DetectedThe page has removed a section titled 'Helpful Links Provided by Blueprint Medicines Corporation' which included additional information about the study.SummaryDifference0.4%
- Check13 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check20 days agoChange DetectedThe web page has been updated to reflect a new version of the study protocol for avapritinib in treating indolent systemic mastocytosis, with significant details about the study's structure and patient assignment being clarified.SummaryDifference22%
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check42 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check78 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
Stay in the know with updates to Avapritinib vs Placebo in Indolent Systemic Mastocytosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Avapritinib vs Placebo in Indolent Systemic Mastocytosis Clinical Trial page.